<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01002820</url>
  </required_header>
  <id_info>
    <org_study_id>1042-0602</org_study_id>
    <nct_id>NCT01002820</nct_id>
  </id_info>
  <brief_title>A Treatment Use Protocol for Subjects Continuing on From the Open-label Extension 0601</brief_title>
  <acronym>0602</acronym>
  <official_title>A Treatment Protocol for Ganaxolone as add-on Therapy in Adult Patients With Uncontrolled Partial-onset Seizures Deriving Benefit From Protocol 1042-0601</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Marinus Pharmaceuticals</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Marinus Pharmaceuticals</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study is designed to provide ganaxolone to those patients deriving significant benefit&#xD;
      from current treatment in protocol 1042-0601.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>October 2009</start_date>
  <completion_date type="Actual">August 2013</completion_date>
  <primary_completion_date type="Actual">October 2010</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>safety as determined by adverse events</measure>
    <time_frame>one year</time_frame>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">11</enrollment>
  <condition>Epilepsy, Complex Partial</condition>
  <arm_group>
    <arm_group_label>participants</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>all subjects participating in 0602 are receiving ganaxolone for seizure control</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ganaxolone</intervention_name>
    <description>liquid suspension, 50 mg/mL, up to 500 mg/day TID or 1500 mg/day, up to 1 year</description>
    <arm_group_label>participants</arm_group_label>
    <other_name>CCD 1042</other_name>
    <other_name>CAS 383-98323-2</other_name>
    <other_name>3 alpha-hydroxy, 3 beta-methyl, 5 alpha-pregnan-20-one</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  subjects who have completed all study visits from previous protocol 1042-0601 and have&#xD;
             been deemed eligible by the Investigator as:&#xD;
&#xD;
          -  having had no major adverse events thought to be drug related&#xD;
&#xD;
          -  deriving benefit from ganaxolone treatment&#xD;
&#xD;
          -  be properly informed of the nature and risks of the study and give written informed&#xD;
             consent prior to study entry&#xD;
&#xD;
          -  must be willing to use a medically acceptable method of birth control and if female of&#xD;
             child-bearing potential, have a negative qualitative serum pregnancy test&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  significant medical or surgical condition at screening or that develops during&#xD;
             protocol participation that might compromise hematologic, cardiovascular, pulmonary,&#xD;
             renal, gastrointestinal, or hepatic systems, or other conditions that would place the&#xD;
             subject under increased risk&#xD;
&#xD;
          -  unwilling to use a double-barrier method of birth control or submit to a serum&#xD;
             pregnancy test&#xD;
&#xD;
          -  history of chronic non-compliance with drug regimens&#xD;
&#xD;
          -  females currently breastfeeding&#xD;
&#xD;
          -  AST or ALT levels greater than 3 times the upper limit of normal at screen&#xD;
&#xD;
          -  Inability to withhold grapefruit or grapefruit products during the study&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Joseph Hulihan, MD</last_name>
    <role>Study Director</role>
    <affiliation>Marinus Pharmaceuticals, Inc.</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of Southern California, Dept of Neurology</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90033</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Kentucky, Dept of Neurology</name>
      <address>
        <city>Lexington</city>
        <state>Kentucky</state>
        <zip>40536</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Albany Medical Center, Dept of Neurology</name>
      <address>
        <city>Albany</city>
        <state>New York</state>
        <zip>12208</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ohio State University</name>
      <address>
        <city>Columbus</city>
        <state>Ohio</state>
        <zip>43210</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Riddle Health Care Center II</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19063</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Thomas Jefferson University, Comprehensive Epilepsy Center</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19107</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Virginia Commonwealth University</name>
      <address>
        <city>Richmond</city>
        <state>Virginia</state>
        <zip>23298</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>August 2020</verification_date>
  <study_first_submitted>October 16, 2009</study_first_submitted>
  <study_first_submitted_qc>October 23, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 27, 2009</study_first_posted>
  <disposition_first_submitted>April 18, 2012</disposition_first_submitted>
  <disposition_first_submitted_qc>April 18, 2012</disposition_first_submitted_qc>
  <disposition_first_posted type="Estimate">April 20, 2012</disposition_first_posted>
  <last_update_submitted>August 19, 2020</last_update_submitted>
  <last_update_submitted_qc>August 19, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">August 26, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Epileptic Seizures</keyword>
  <keyword>Seizure Disorder</keyword>
  <keyword>Seizures</keyword>
  <keyword>Convulsions</keyword>
  <keyword>Anticonvulsant</keyword>
  <keyword>Anticonvulsive</keyword>
  <keyword>Antiepileptic</keyword>
  <keyword>Ganaxolone</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Epilepsy, Complex Partial</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ganaxolone</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted, but a results disposition has been submitted           -->
</clinical_study>

